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The transforming growth factor b (TGFb)-signalling pathway is deregulated in many cancers. We examined the role of gene silencing
via aberrant methylation of DRM/Gremlin and HPP1, which inhibit TGFb signalling, and RUNX3, which facilitates TGFb-signalling, of all
genes that are thought to be tumour suppressors, are aberrantly expressed, and are thus thought to have important role in human
cancers. We examined DRM/Gremlin mRNA expression in 44 cell lines and the promoter methylation status of DRM/Gremlin, HPP1,
and RUNX3 in 44 cell lines and 511 primary tumours. The loss of DRM/Gremlin mRNA expression in human cancer cell lines is
associated with DNA methylation, and treatment with the methylation inhibitor-reactivated mRNA expression (n¼13). Methylation
percentages of the three genes ranged from 0–83% in adult tumours and 0–50% in paediatric tumours. Methylation of DRM/Gremlin
was more frequent in lung tumours in smokers, and methylation of all three genes was inversely correlated with prognosis in patients
with bladder or prostate cancer. Our results provide strong evidence that these TGFb-related genes are frequently deregulated
through aberrant methylation in many human malignancies.
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The transforming growth factor b (TGFb) superfamily of paracrine
and autocrine signalling molecules regulates many intra- and
extracellular functions, including development, proliferation,
differentiation, extracellular matrix and bone formation, angio-
genesis, and immune responses (Balemans and Van Hul, 2002;
Gumienny and Padgett, 2002). The TGFb family includes TGFbs,
bone morphogenetic proteins (BMPs), activins, and several other
subfamilies. Transforming growth factor b family members and
their receptors are expressed by many types of normal and
malignant cells. Both upregulation and downregulation of TGFb
family member signalling may occur in cancer cells during
different stages of pathogenesis (de Caestecker et al, 2000; Teicher,
2001; Roberts and Wakefield, 2003). Downregulation frequently
occurs early in tumour development and is associated with
increased epithelial growth and inhibition of apoptosis, while
upregulation is more frequent during later stages and is associated
with increased angiogenesis, stromal remodelling, suppression of
immune responses, and metastatic spread. These cellular changes
may occur via deregulation of interaction with Smad proteins at
the nuclear level, via increased secretion of ligands by tumour
cells, and/or by inactivation of ligands by soluble or intracellular
inhibitors (de Caestecker et al, 2000; Teicher, 2001; Roberts and
Wakefield, 2003).
A large number of soluble inhibitors of TGFb family members
have been identified (Gumienny and Padgett, 2002). The DRM/
Gremlin (CKTSF1B1) gene, a member of the Cerberus/Dan family
of BMP-soluble antagonists (Pearce et al, 1999), was independently
isolated by two groups (Topol et al, 1997; Hsu et al, 1998). Topol
et al (1997) isolated Drm from a rat model in which they
demonstrated that transfection of Drm induced apoptosis and
inhibited growth in rat fibroblasts. Hsu et al (1998) isolated
Gremlin in Xenopus and demonstrated that it was a secreted
protein that functioned as a BMP antagonist. DRM/Gremlin has
been reported to influence BMP2-associated signalling pathways
stimulated by fibroblast growth factor (Zuniga et al, 1999) and
platelet-derived growth factor (PDGF) (Ghosh Choudhury et al,
1999), and it also negatively modulates embryonic lung morpho-
genesis (Shi et al, 2001).
Although the importance of DRM/Gremlin has been demonstrated
during development and in the pathogenesis of nephropathy (Zuniga
et al, 1999; McMahon et al, 2000; Khokha et al, 2003), its role in
cancer pathogenesis is poorly understood. Topol et al (2000) recently
mapped the human homologue of DRM/Gremlin to chromosome
15q13–15 and demonstrated that DRM/Gremlin mRNA expression is
downregulated in several human tumour types. These researchers
also found that the DRM/Gremlin transcript is normally expressed
only in healthy breast epithelium. While these findings suggest that
DRM/Gremlin is a tumour suppressor gene (TSG), how it is silenced
in cancer cells is not known.
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sThe HPP1 (TMEFF2) gene belongs to another, possibly unique,
class of TGFb antagonists. HPP1 is a transmembrane receptor
containing two follistatin modules and a single epidermal
growth factor (EGF)-like domain (Uchida et al, 1999). Follistatin,
a secreted soluble inhibitor, binds and neutralises the activity of
many TGFb family members, including BMPs and activins, as
well as PDGF and vascular endothelial growth factor (Patel, 1998;
Lin et al, 2003). The EGF-like domain in HPP1 appears to be a
ligand for c-erbB-4 (Uchida et al, 1999). Recently, Gery et al (2002)
demonstrated that HPP1 exhibits antiproliferative effects in
prostate cancer cell lines . These researchers also demonstrated
an inverse correlation between HPP1 activity in prostate cancer
xenografts and c-Myc expression (Gery and Koeffler, 2003). Two
soluble forms of HPP1 protein that differ in the presence/absence
of the EGF-like domain arise by proteolytic cleavage (Uchida et al,
1999). Currently, it is not known which isoforms of HPP1 are
responsible for its tumour suppressor function. HPP1 maps to
chromosome 2q32.3, where loss of heterozygosity (LOH) fre-
quently occurs in a number of tumours types, including lung
cancer and breast cancer (Otsuka et al, 1996; Huiping et al, 1999).
RUNX3 is a Runt domain transcription factor that interacts
with Smad proteins, suggesting that it may play an important role
in TGFb signalling. This gene is a candidate TSG localised to 1p36,
a region commonly deleted in a wide variety of human cancers,
including lung cancer and breast cancer (Ragnarsson et al, 1999;
Girard et al, 2000).
DNA methylation in the 50 region is emerging as the primary
mechanism of TSG inactivation (Jones and Baylin, 2002; Suzuki
et al, 2004). Aberrant methylation of the HPP1 and RUNX3 genes
has been demonstrated in gastrointestinal and other human
tumours (Liang et al, 2000; Young et al, 2001; Guo et al, 2002; Li
et al, 2002; Sato et al, 2002; Shibata et al, 2002; Kato et al, 2003;
Xiao and Liu, 2004).
Using a microarray strategy, we recently identified DRM/
Gremlin as a gene that was differentially expressed in a non-
small-cell lung carcinoma (NSCLC) cell line after treatment with a
demethylating agent (5-aza-20-deoxycytidine (5-Aza-CdR)). Inter-
estingly, lung cancer cell lines frequently demonstrate LOH at this
gene location (Girard et al, 2000).
In this study, we examined mRNA expression and methylation
status of DRM/Gremlin in lung cancer, breast cancer, and
malignant mesothelioma (MM) cell lines, as well as the methyla-
tion status of DRM/Gremlin, HPP1, and RUNX3 in several primary
malignant tumours.
MATERIALS AND METHODS
Cell lines and tumour samples
In all, 28 lung cancer cell lines (15 NSCLC cell lines and 13 small-
cell lung cancer (SCLC)] cell lines), 10 breast cancer cell lines, and
six MM cell lines that were established by our group (Phelps et al,
1996; Gazdar et al, 1998) and deposited in the American Type
Culture Collection (Manassas, VA, USA), were used in this study.
Cell cultures were grown in RPMI-1640 medium (Life Technologies
Inc., Rockville, MD, USA) supplemented with 5% fetal bovine
serum and incubated in 5% CO2 at 371C. Cell lines established
at the National Cancer Institute have the prefix NCI while those
established at UT Southwestern Medical Center have the prefix
HCC. Normal bronchial epithelial cells (NHBEC), normal mam-
mary epithelial cells (NHMEC), and normal mesothelial cells
(NMC) were cultured as reported previously (Suzuki et al, 2005),
and normal trachea RNA was obtained from Clontech (Palo Alto,
CA, USA).
In all, 13 tumour cell lines with DRM/Gremlin methylation and
lack of DRM/Gremlin gene expression were incubated in culture
medium with 4mM (5-Aza-CdR) for 6 days, with medium changes
on days 1, 3, and 5. Cells were harvested and RNA was extracted on
day 6.
Primary lung tumours were obtained from the Chiba University
Hospital, Japan, and other tumours were obtained from the
hospital system of the University of Texas Southwestern Medical
Center, after obtaining Institutional Review Board approval and
signed informed consent. Samples were immediately frozen and
stored at  801C until use.
Reverse transcriptase–PCR (RT–PCR) assay for DRM/
Gremlin
An RT–PCR assay was used to examine DRM/Gremlin mRNA
expression. Total RNA was extracted from samples with Trizol (Life
Technologies, Rockville, MD, USA) following the manufacturer’s
Table 1 Methylation and expression of DRM/Gremlin in cell lines
DRM/Gremlin
Samples Expression (%) Methylation (%)
Lung cancer cell lines (n¼28)
NSCLC (n¼15) 3 (20) 11 (73)
SCLC (n¼13) 8 (62) 4 (31)
Breast cancer cell lines (n¼10) 5 (50) 5 (50)
MM cell lines (n¼6) 2 (33) 4 (67)
NHBEC (n¼1) 1 (100) 0 (0)
NHMEC (n¼2) 2 (100) 0 (0)
NMC (n¼3) 3 (100) 0 (0)
MM¼malignant mesothelioma; NHBEC¼normal human bronchial epithelial cells;
NHMEC¼normal human mammary epithelial cells; NMC¼normal human
mesothelial cells.
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Figure 1 RT–PCR for DRM/Gremlin (CKTSF1B1) expression in lung and
breast cancer cell lines. (A) Representative examples of RT–PCR results
for DRM/Gremlin expression. (B) Effect of 5-Aza-CdR treatment on DRM/
Gremlin-negative cell lines with DRM/Gremlin methylation. Treatment with
5-Aza-CdR restored expression of DRM/Gremlin in all 13 methylated cell
lines tested. Expression of the housekeeping gene GAPDH was measured as
a control for RNA integrity. M, molecular size marker; LC, lung cancer; BC,
breast cancer; MM, malignant mesothelioma; NEG, negative control
(genomic DNA). Before (B) and after (A) treatment with 5-Aza-CdR.
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sinstructions. The RT reaction was performed on 4mg total RNA
with Deoxyribonuclease I and the SuperScript II First-Strand
Synthesis using the oligo(dT) primer System (Life Technologies),
and aliquots of the reaction mixture were used for subsequent PCR
amplification. Primer sequences for DRM/Gremlin amplification
were: forward, 50-ACTCAGCGCCACGCGTCGAAA-30; reverse,
50-ACTGAGTCTGCTCTGAGTCATT-30 (GenBank accession num-
ber AC090877; forward, nucleotides 52619–52639; reverse, nucleo-
tides 65324–65345), and we confirmed that genomic DNA was not
amplified with these primers which cross an intron. The
amplification programme for the DRM/Gremlin transcript was
1min at 941C, 1min at 601C, and 1min at 721C for 40 cycles. The
housekeeping gene GAPDH was used as an internal control to
confirm the success of the RT reaction. Primer sequences for
GAPDH amplification were: forward, 50-CACTGGCGTCTTCAC
CACCATG-30; reverse, 50-GCTTCACCACCTTCTTGATGTCA-30
(GenBank accession number NM_002046). These primer se-
quences were identical to the endogenous human target genes as
confirmed by a BLAST search. PCR products were analysed on 2%
agarose gels. Normal bronchial epithelial cells, NHMEC, NMC, and
normal trachea were used as normal controls for RT–PCR.
Map of the 50 flanking region of DRM/Gremlin and
bisulphite DNA sequencing
The locations of CpG dinucleotides, the MSP amplicon (region of
MSP (RMSP)), and the area that underwent bisulphite DNA
sequencing (region of bisulphite sequencing (RBSSQ)) in the 50
region of DRM/Gremlin are shown in Figure 3. Bisulphite-treated
DNA was PCR-amplified using the following primers: forward,
50-TGTGATTTGTTGTGTATTTTAGG-30; reverse, 50-ATAATTCTT
CACAATTCACCCC-30 (GenBank accession number AC090877,
Type Methylated Unmethylated mRNA 5-Aza-CdR
NCI-H78 N
NCI-H1437 N ND
NCI-H1395 N ND
NCI-H157 N ND
NCI-H2347 N ND
NCI-H1770 N ND
NCI-H1299 N ND
HCC1171 N
NCI-H2122 N
NCI-H2887 N ND
NCI-H2087 N ND
NCI-H515 N
NCI-H15 N ND
HCC95 N
NCI-H358 N
NCI-H209 S ND
NCI-H2171 S ND
NCI-H2195 S
NCI-H146 S ND
NCI-H1607 S ND
NCI-H82 S ND
NCI-H1184 S ND
NCI-H2141 S ND
NCI-H970 S ND
NCI-H524 S ND
NCI-H526 S ND
NCI-H211 S
NCI-H187 S ND
HCC38 B ND
HCC202 B
HCC1007 B ND
HCC1008 B ND
HCC1395 B ND
HCC1143 B ND
HCC1937 B ND
HCC1954 B
HCC1419 B ND
HCC2218 B
NCI-H28 M
NCI-H226 M ND
NCI-H290 M
NCI-H513 M ND
NCI-H2052 M ND
NCI-H2452 M ND
Figure 2 DRM/Gremlin (CKTSF1B1) expression and methylation in tumour cell lines. Closed box, positive (POS) band detected; open box, negative
(NEG) band detected; N, NSCLC cell line; S, SCLC cell line; B, breast cancer cell line; M, MM cell line; ND, not done.
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s52248–52821, 574bp). These primers were designed to exclude
binding to any CpG dinucleotides to ensure amplification of
both methylated and unmethylated sequences. PCR products were
cloned into plasmid vectors using the Topo TA cloning kit
(Invitrogen, Carlsbad, CA, USA) following the manufacturer’s
instructions. Five positive clones were purified from each test cell
line using the Wizard Plus miniprep kit (Promega), and were then
sequenced by the Applied Biosystems PRISM dye terminator cycle
sequencing method (Perkin-Elmer Corp., Foster City, CA). This
region included the MSP primer sites and amplicon and
encompassed 77 CpG dinucleotides.
DNA extraction and methylation-specific PCR
Genomic DNA was obtained from cell lines, primary tumours, and
normal cells by digestion with proteinase K (Life Technologies),
followed by phenol/chloroform (1:1) extraction (Suzuki et al,
2003). DNA methylation patterns in the CpG island of DRM/
Gremlin were determined by the methylation-specific PCR (MSP)
method as reported as described previously (Herman et al, 1996).
Primer sequences of DRM/Gremlin for methylated reaction were as
follows: forward, 50-ATTTAAACGGGAGACGGCGCG-30; reverse,
50-GACCAAAACCGCCGAAACTCG-30; those for the unmethylated
reaction were: forward, 50-ATTTAAATGGGAGATGGTGTG-30;
reverse, 50-AACCAAAACCACCAAAACTCA-30. Primer sequences
for amplification of HPP1 and RUNX3 for MSP have been
previously described (Li et al, 2002; Sato et al, 2002). Briefly,
1mg genomic DNA was denatured by NaOH and modified by
bisulphite. The modified DNA was purified using Wizard DNA
purification kit (Promega), treated with NaOH to desulfonate,
precipitated with ethanol and resuspended in water. PCR
amplification was performed with bisulphite-treated DNA as a
template using specific primer sequences for the methylated and
unmethylated forms of the genes. DNA from peripheral blood
lymphocytes (n¼10) from healthy subjects (non-smoking) was
used as negative controls for MSP assays. DNA from lymphocytes
of a healthy volunteer treated with Sss1 methyltransferase (New
England BioLabs, Beverly, MA) and then subjected to bisulphite
treatment was used as a positive control for methylated alleles.
Water blanks were included with each assay. Results were
confirmed by repeating bisulphite treatment and MSP for all
samples.
Data analysis
Statistical differences between groups were examined using
Fisher’s exact test, the chi-square test, and the Mann-Whitney
test. Survival was calculated from the date of initial diagnosis until
death or the date of the last follow-up (censored). Survival was
analysed according to the Kaplan-Meier method, and differences
in distribution were evaluated by means of the log-rank test. A
P-value of less than 0.05 was defined as being statistically significant.
RESULTS
DRM/Gremlin mRNA expression in normal and malignant
breast, lung, and mesothelial cells
We used RT–PCR to examine the expression of DRM/Gremlin
(Table 1); representative examples are shown in Figure 1A. DRM/
Gremlin mRNA was detected in NHBEC, normal trachea, NHMEC,
and NMC, indicating that this gene is normally expressed in
Normal
lung tissue
Lymphocyte
NCI-H157
HCC38
NCI-H211
10 20 30 40 50 60 70
NCI-H515
NCI-H2347
HCC202
RBSSQ (DRM/Gremlin)
–363 +211
TSS
Exon 1
100 bp
10 20 30 40 50 60 70
MSP (+)
RT–PCR (–)
MSP (+)
RT–PCR (–)
MSP (+)
RT–PCR (–)
MSP (–)
MSP (–)
RT–PCR (+)
MSP (–)
RT–PCR (+)
MSP (–)
MSP (–)
NCI-H28
RT (–)
Aza (+)
NCI-H290
RT (–)
Aza (+)
RT–PCR (+)
Figure 3 The location and methylation status of methylated CpG dinucleotides in the region of DRM/Gremlin that underwent bisulphite genomic DNA
sequencing (RBSSQ). Positive numbers indicate the nucleotide position from the transcription start site (TSS; indicated with an arrow). Thin vertical lines and
the numbers indicate the positions of CpG dinucleotides in the RBSSQ. The horizontal closed bars between numbers indicate the positions of CpG
dinucleotides included in the MSP primers. Open circles indicate unmethylated CpG sites and filled circles indicate methylated CpG sites.
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srespiratory cells, breast epithelial cells, and mesothelial cells.
However, loss of DRM/Gremlin expression was observed in 12/15
(80%) of NSCLC cell lines, 5/13 (38%) of SCLC cell lines, 5/10
(50%) of breast cancer cell lines, and 4/6 (67%) of MM cell lines
(Table 1 and Figure 2).
Bisulphite genomic DNA sequencing of the 50 region of
DRM/Gremlin
We sequenced bisulphite-treated DNA in the 50 region of DRM/
Gremlin to clarify any correlation between DNA methylation and
gene silencing in various cancer cell lines. Using methylation-
independent primers, we amplified and sequenced the 50 region
and exon 1 of the DRM/Gremlin gene (Figure 3). The 574-bp
amplicon contains 77 CpG dinucleotides as well as exon 1. The
translation start site is in exon 2. The GþC percentage is 74%,
with a CpG ratio of 1. This region therefore satisfied the criteria
for a CpG island (Gardiner-Garden and Frommer, 1987). Eight cell
lines showed an excellent concordance between MSP and RT–PCR
assay results and clonal sequencing results. Two normal tissues
(normal lung and peripheral blood lymphocytes) also showed
concordance between MSP assay and sequencing results. We
developed MSP primers based on these sequencing results.
DNA methylation of DRM/Gremlin in cell lines and tissues
The DNA methylation status of DRM/Gremlin in cell lines as
assessed by MSP assays are detailed in Table 1 and Figure 3, and
representative examples are illustrated in Figure 4. Methylation
of DRM/Gremlin was absent in DNA from peripheral blood
lymphocytes from healthy volunteers and in respiratory cells,
breast epithelial cells, and mesothelial cells. In contrast, DRM/
Gremlin methylation was detected in 11/15 (73%) of NSCLC cell
lines, 4/13 (31%) of SCLC cell lines, 5/10 (50%) of breast cancer cell
lines, and 4/6 (67%) of MM cell lines. Either the methylated or
the unmethylated forms of the gene were present in most cell lines
(37/44 (84%)), while both forms were present in the remaining
seven (16%) cell lines. Overall concordance between DRM/Gremlin
expression and methylation was 42/44 (95%).
Restoration of DRM/Gremlin expression in
5-Aza-CdR-treated cancer cells
A total of 13 tumour cell lines (five NSCLC, one SCLC, three breast
cancer, and four MM) that showed loss of expression and
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Figure 4 Representative examples of MSP results for DRM/Gremlin in
cell lines and primary tumours. (A) Representative examples of MSP results
for DRM/Gremlin in lung cancer cell lines, breast cancer cell lines, and MM
cell lines. DRM/Gremlin M, DRM/Gremlin-methylated form; DRM/Gremlin U,
DRM/Gremlin-unmethylated; POS, positive control, that is, artificially
methylated DNA; NEG, negative control (water blank). (B) Lung cancer
(T), matched normal lung tissue (N), breast cancer (T), matched normal
breast tissue (N). (C) MM, malignant pleural mesothelioma; BC, bladder
cancer; PCa, prostate cancer; ML, malignant lymphoma. A visible band
indicates amplification of a methylated form of a gene. Owing to
contamination by normal tissues, either the unmethylated band only or
both the methylated and unmethylated bands were present in several
samples.
Table 2 Methylation of DRM/Gremlin, HPP1, and RUNX3 in human
cancers
No. methylated (%)
Samples Total no. DRM/Gremlin HPP1 RUNX3
Adult tumours 367
Primary NSCLC
Adenocarcinoma 60 22 (37) 18 (30) 13 (22)
Squamous cell carcinoma 51 40 (78) 15 (29) 8 (16)
Large cell carcinoma 6 5 (83) 4 (67) 4 (67)
Primary SCLC 5 3 (60) 2 (40) 0
Bronchial carcinoid 18 0 0 0
Malignant mesothelioma 63 38 (60) 22 (35) 21 (33)
Breast cancer 37 20 (54) 13 (35) 8 (22)
Prostate cancer 50 10 (20) 19 (38) 5 (10)
Bladder cancer 57 29 (51) 20 35) 24 (42)
Lymphoma 20 10 (50) 6 (30) 1 (5)
Paediatric tumours 150
Osteosarcoma 10 1 (10) 0 5 (50)
Wilm’s tumour 25 0 0 0
Neuroblastoma 27 0 0 0
Rhabdomyosarcoma 17 1 (6) 0 0
Medulloblastoma 12 0 0 0
Hepatoblastoma 22 0 0 0
Ewing sarcoma 7 0 0 0
Retinoblastoma 30 0 0 0
Normal tissues 138
Lung tissues
a and NHBEC 51 1 (2) 0 0
Mesothelial cells 3 0 0 0
Breast tissues
a 23 0 0 0
Protate tissues
a 40 0 0
Bladder tissues
a 50 0 0
Peripheral blood lymphocytes
b 14 0 0 0
aAdjacent to resected tumours.
bFrom healthy volunteers.
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sTable 3 Clinicopathologic correlation with the methylation of DRM/Gremlin, HPP1 and RUNX3 in adult solid tumours
Clinicopathologic features DRM/Gremlin methylation (%) P
a HPP1 methylation (%) P RUNX3 methylation (%) P
Lung cancers
Gender
Male (n¼88
b) 68 (77) 0.008 25 (28) 0.3 18 (20) 0.9
Female (n¼35) 18 (51) 14 (40) 7 (20)
Age
c
p65 (n¼60) 42 (70) 0.9 19 (32) 0.9 13 (22) 0.8
465 (n¼63) 44 (70) 20 (32) 12 (19)
Smoking history
Nonsmoker (n¼26) 12 (46) 0.007 8 (31) 0.9 5 (19)
Smoker (n¼97) 74 (76) 31 (32) 20 (21) 0.9
Histology
Adenocarcinoma (n¼60) 38 (63) 18 (30) 13 (22)
Squamous cell ca. (n¼51) 40 (78) 15 (29) 8 (16)
Large cell ca. (n¼6) 5 (83) 4 (67) 4 (67)
Small cell ca. (n¼5) 3 (60) 2 (40) 0 (0)
Carcinoid (n¼18) 0 (0) 0 (0) 0 (0)
Postsurgical stage
Stages I and II (n¼52) 42 (81) 0.03 19 (36) 0.3 8 (15) 0.3
Stages III and IV (n¼71) 44 (62) 20 (28) 17 (24)
Breast cancers
Age
p53 (n¼17) 5 (29) 0.009 3 (18) 0.08 2 (12) 0.2
453 (n¼20) 15 (75) 10 (50) 6 (30)
Postsurgical stage
Stages I and IIA (n¼21) 9 (43) 0.1 5 (24) 0.2 5 (24) 0.9
Stages IIB and IIIA (n¼16) 11 (69) 8 (50) 3 (19)
Estrogen receptor status
Positive (n¼22) 14 (64) 0.4 11 (50) 0.08 8 (36) 0.02
Negative (n¼11) 6 (55) 2 (18) 0 (0)
Progesterone receptor status
Positive (n¼20) 13 (65) 0.4 10 (50) 0.1 7 (35) 0.08
Negative (n¼13) 7 (54) 3 (23) 1 (8)
Bladder cancers
Gender
Male (n¼36) 19 (53) 0.8 12 (33) 0.8 14 (39) 0.6
Female (n¼21) 10 (48) 8 (38) 10 (48)
Age
p67 (n¼29) 14 (48) 0.8 10 (34) 0.9 12 (41) 0.9
467 (n¼28) 15 (54) 10 (36) 12 (43)
Grade
Grades 1 and 2 (n¼13) 5 (38) 0.5 2 (15) 0.2 2 (15) 0.05
Grade 3 (n¼43) 23 (53) 17 (40) 21 (49)
Growth pattern
Nonpapillary (n¼26) 15 (58) 0.4 10 (38) 0.8 13 (50) 0.3
Papillary (n¼31) 14 (45) 10 (32) 11 (35)
Muscle invasion
Noninvasion (n¼18) 7 (39) 0.3 3 (17) 0.07 4 (22) 0.048
Invasion (n¼39) 22 (56) 17 (44) 20 (51)
Stage
Stages 0–II (n¼16) 4 (25) 0.03 1 (6) 0.003 3 (19) 0.1
Stages III and IV (n¼30) 18 (60) 15 (50) 14 (47)
Prostate cancers
Age
p64 (n¼27) 6 (22) 0.7 7 (26) 0.2 1 (4) 0.2
464 (n¼26) 4 (15) 12 (46) 4 (15)
Gleason score
p6( n¼22) 6 (27) 0.3 11 (50) 0.2 1 (5) 0.4
X7( n¼28) 4 (14) 8 (29) 4 (14)
Preoperative serum PSA
d
p7.5ng/ml (n¼25) 5 (20) 0.7 8 (32) 0.9 2 (8) 0.9
X7.5ng/ml (n¼22) 3 (14) 7 (32) 2 (9)
aFisher’s exact probability test.
bDetailed data were available on the number in parentheses.
cDevided by median age.
dProstate-specific antigen.
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smethylation of DRM/Gremlin were cultured with 5-Aza-CdR.
DRM/Gremlin expression was restored after treatment in all 13
cell lines (Figure 1B).
DNA methylation of DRM/Gremlin, HPP1, and RUNX3 in
primary tumours and tissues and its correlation to
clinicopathologic features
DRM/Gremlin is aberrantly methylated and downregulated in
thoracic cancer cell lines. HPP1 and RUNX3 have also been
shown to be aberrantly methylated in certain cancer types. These
three genes are TGFb related and are all thought to be tumour
suppressors. We next examined the methylation status of these
three genes in primary tumours and tissues by MSP assay (Tables 2
and 3, Figure 4). Methylation of DRM/Gremlin was observed in
50% of lung cancer tissues (n¼140), 54% of breast cancer tissues
(n¼37), and 60% of MM tissues (n¼63), while methylation of
HPP1 in these tissues occurred at a frequency of 28, 35, and 35%,
respectively, and methylation of RUNX3 occurred at a frequency of
18, 22, and 33%, respectively. The methylation frequency for all
three genes was significantly higher in adult tumours compared to
paediatric tumours (DRM/Gremlin, Po0.0001; HPP1, Po0.0001;
RUNX3, Po0.0001). Methylation of all three genes appeared to
be tumour specific in all adult tumours, when compared to
corresponding adjacent normal tissues (Po0.0001). Methylation of
these genes was not detected in bronchial carcinoids.
In lung cancer tissue, DRM/Gremlin methylation was not
associated with age, postsurgical stage, or prognosis, but it was
associated with gender (male, 68/88 (77%); female, 18/35 (51%);
P¼0.008) and smoking history (smoker, 74/97 (76%); nonsmoker,
12/26 (46%); P¼0.007). In breast cancer samples, methylation of
DRM/Gremlin gene was associated with older age (P¼0.009). In
addition, the frequency of methylation for RUNX3 was higher in
estrogen receptor (ER)-positive cases than in ER-negative cases
(ER positive, 8/22 (36%); ER negative, 0/8 (0%); P¼0.02). In
bladder cancer tissues, methylation of DRM/Gremlin was asso-
ciated with poorer prognosis (P¼0.026, log-rank test) (Figure 5).
The frequencies of methylation for DRM/Gremlin and HPP1 were
higher in advanced-stage bladder cancer cases (stages III–IV) than
in early-stage cases (stages 0–II, P¼0.03 and 0.003, respectively).
The frequency of methylation for RUNX3 was higher in the
presence of muscle invasion cases (20/39 (51%)) than in the
absence of muscle invasion cases (4/18 (22%); P¼0.048). In
prostate cancer tissues, methylation of these three genes did not
appear to be correlated with age, stage, Gleason score, or serum
prostate-specific antigen level. However, RUNX3 and HPP1
methylation-positive status were associated with poorer disease-
free prognosis (P¼0.007 and 0.014, respectively; log-rank test).
DISCUSSION
DRM/Gremlin encodes a 184-amino-acid protein that is a member
of the cysteine knot superfamily (Hsu et al, 1998). This protein has
been highly conserved during evolution and it belongs to a novel
family of BMP antagonists that includes the tumour suppressor
DAN. The BMPs play a major role in bone formation and may
facilitate bone metastases derived from prostate tumours (Masuda
et al, 2003) as well as other cancers. DRM/Gremlin protein blocks
the activity of BMP2, BMP4, and BMP7 with high affinity (Hsu
et al, 1998; Merino et al, 1999) and possibly that of other growth
factors in the TGFb superfamily. BMP2 is overexpressed in NSCLC
tissues and has been shown to stimulate growth of A549 lung
cancer cells (Langenfeld et al, 2003). DRM/Gremlin is also known
to affect lung development (Shi et al, 2001). BMP2 exposure has
been shown to increase phosphatase and tensin homolog (PTEN)
protein levels in the breast cancer cell line MCF-7 (Waite and Eng,
2003). Blocking BMP signalling by overexpression of a dominant-
negative type II BMP receptor inhibits the growth of human breast
cancer cells (Pouliot et al, 2003). Recently, Chen et al demon-
strated that overexpression of Drm in the tumour-derived cell
lines Daoy (primitive neuroectodermal, HTB186) and Saos-2
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Figure 5 Survival curves of bladder and prostate cancer cases. Survival
was analysed according to the Kaplan–Meier method, and differences in
distribution were evaluated using the log-rank test. (A) Overall survival
curve according to DRM/Gremlin methylation status in bladder cancer cases
(n¼57). (B) Disease-free survival curve of prostate cancer cases (n¼28)
according to RUNX3 and HPP1 methylation status. Poorer overall and
disease-free survival were observed in bladder cancer cases with DRM/
Gremlin methylation and in prostate cancer cases with RUNX3 and HPP1
methylation.
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s(osteoblastic, HTB-85) transcriptionally activates p21
Cip1 via a
novel mechanism, independent of p53 and both p38 and p42/44
MAP kinases, and inhibits neoplastic transformation (Chen et al,
2002). Thus, silencing of the DRM/Gremlin gene by DNA
methylation may play a role in carcinogenesis both by affecting
the cell cycle as well as by upregulation of BMP signalling.
We observed frequent methylation of DRM/Gremlin in many
human adult cancer tissues and cell lines, and methylation
appeared to be correlated with reduced DRM/Gremlin mRNA
expression, suggesting that epigenetic phenomena (i.e., methyla-
tion and the related mechanism of histone deacetylation) were
the major causes of gene silencing. Expression of these genes was
reactivated following treatment with the demethylating agent
5-Aza-CdR, providing further evidence that methylation is indeed
the silencing mechanism involved.
Methylation of DRM/Gremlin, HPP1, and RUNX3 appeared to
be tumour specific in these cancer types when compared to
corresponding adjacent normal tissues. Methylation of these genes
in paediatric tumours was relatively rare, which is consistent with
our previous reports (Harada et al, 2002). Methylation of these
genes was not detected in bronchial carcinoids, which are lung
tumours with relatively low invasive and metastatic potential. In a
previous study, we found that the methylation profile of carcinoids
was similar to that of SCLC, although the methylation frequencies
of most genes were lower in carcinoids (Toyooka et al, 2001).
In our previous studies, we observed that the methylation
frequencies of MGMT and GSTP1 in lung cancers were
significantly higher in US and Australian cases than in those
from Japan and Taiwan (Toyooka et al, 2003). In addition,
methylation frequencies were either similar, or slightly higher
(seldom significantly) in lung tumour cell lines than in primary
tumours (Toyooka et al, 2001). In our present series, the
primary lung tumours were from Japan while all of the other
primary tumours as well as the cell lines were from the US.
Although the methylation frequencies of DRM/Gremlin between
primary tumours and cell lines for lung cancer, breast cancer, and
MM were similar, further interethnic studies need to be performed
to clarify this matter.
Although only a small number of breast cancer tissues were
examined, tissues from older women showed a higher frequency of
DRM/Gremlin methylation than did those from young women.
Age-related methylation of TSGs has also been reported in colonic
epithelium and cancer (Waki et al, 2003). Methylation of DRM/
Gremlin was significantly more frequent in lung cancers arising in
smokers compared to nonsmokers. We and others have noted a
relationship between the methylation of certain genes, including
p16 and APC, as well as an increased overall methylation status in
smoking-related lung cancers (Kim et al, 2001; Toyooka et al,
2003). In bladder cancers, DRM/Gremlin methylation-positive
status was associated with poorer prognosis, while RUNX3 and
HPP1 methylation-positive status was associated with poorer
disease-free prognosis in prostate cancers. Although the number
of samples tested in this study is too small to draw definitive
conclusions, deregulation of TGFb signalling through hypermethy-
lation of these genes may affect tumour progression as well as
patients’ prognosis, resulting in more aggressive local and distant
metastatic spread, including the bone. Of interest, bone metastases
are frequent in the cancers examined in this study, particularly in
SCLC, breast cancer, and prostate cancer.
In conclusion, we found that two inhibitors and one modulator
of TGFb signalling, DRM/Gremlin, HPP1, and RUNX3, respectively,
are often methylated and thereby silenced in human cancers.
Correlation between methylation of any of these genes with various
clinicopathological features, including smoking status and survi-
val, indicates that our findings may be of both biological and
clinical relevance.
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